The FDA Reclassification of Cervical Pedicle and Lateral Mass Screws: A Case Study in Regulatory History

Jonathan H. Sussman,Ahmed Albayar,Anissa Saylany,Bhargavi R. Budihal,Dominic Romeo,Jason Xu,Joshua Rosenow,Robert F. Heary,William C. Welch

DOI: https://doi.org/10.1007/s43441-024-00654-1

2024-04-17

Therapeutic Innovation & Regulatory Science

Abstract:The classification of medical devices by the Food and Drug Administration (FDA) involves rigorous scrutiny from specialized panels that designate devices as Class I, II, or III depending on their levels of relative risk to patient health. Posterior rigid pedicle screw systems were first classified by the FDA in 1984 and have since revolutionized the treatment of many spine pathologies. Despite this early classification by the FDA, posterior cervical pedicle and lateral mass screws were not reclassified from unclassified to Class III and then to Class II until 2019, nearly 35 years after their initial classification. This reclassification process involved a decades-long interplay between the FDA, formal panels, manufacturers, academic leaders, practicing physicians, and patients. It was delayed by lawsuits and a paucity of data demonstrating the ability to improve outcomes for cervical spinal pathologies. The off-label use of thoracolumbar pedicle screw rigid fixation systems by early adopters assisted manufacturers and professional organizations in providing the necessary data for the reclassification process. This case study highlights the collaboration between physicians and professional organizations in facilitating FDA reclassification and underscores changes to the current classification process that could avoid the prolonged dichotomy between common medical practice and FDA guidelines.

pharmacology & pharmacy,medical informatics

What problem does this paper attempt to address?

The paper primarily explores the process by which the U.S. Food and Drug Administration (FDA) classifies medical devices, using the reclassification of cervical pedicle screws and lateral mass screws as a case study. The article first introduces the role of the FDA in medical device classification and its process of categorizing devices into three classes (Class I to Class III) according to the Federal Food, Drug, and Cosmetic Act (FD&C Act).

The core issue of the paper is to elucidate the historical process of how cervical pedicle screws and lateral mass screws were initially classified and eventually reclassified as Class II devices. These devices were widely used in clinical practice during the 1980s and 1990s, but due to a lack of sufficient evidence of safety and efficacy, they were classified as Class III devices, requiring rigorous premarket approval processes. It was not until 2019, based on years of data accumulation and the concerted efforts of manufacturers, academic leaders, practicing physicians, and patients, that these devices were officially reclassified as Class II devices.

The author points out that this long-term process reveals the discrepancies between common practices in existing medical practice and FDA guidelines. Additionally, the paper emphasizes the importance of data collection and analysis, and how to effectively present this data to the FDA to support the reclassification of devices. Finally, the paper proposes some improvements, such as increasing transparency and data sharing, to foster collaboration among physicians, manufacturers, and regulatory agencies, thereby better aligning device classification standards with clinical practice needs.